Xbrane Biopharma to participate at Redeye Biosimilar/Drug Delivery 16 April

Corporate Information

English

News

Other Corporate Information

Xbrane Biopharma AB (publ) ("Xbrane" or "the Company”) represented by Martin Åmark, CEO, will tomorrow participate at Redeye’s capital markets day about Biosimilar/Drug Delivery.

On April 16, at 09:55 AM, Martin Åmark, CEO, Xbrane Biopharma, will present the latest events and development in the Company at Redeye. The presentation will be live and can be followed at https://www.redeye.se/events#/event/585887 where the presentation afterwards will be available on Xbrane’s company page at Redeye Universe https://www.redeye.se/company/xbrane-biopharma.

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company that develop and produces biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane’s headquarter is located in Solna outside of Stockholm and the company’s in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq Stockholm since September 2019 with the ticker XBRANE. For more information please visit www.xbrane.com.